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Abstract: Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating VEGF receptor-2 
(VEGFR-2). The role of its homolog, placental growth factor (PlGF), remains unknown. Both VEGF and PlGF 
bind to VEGF receptor-1 (VEGFR-1), but it is unknown whether VEGFR-1, which exists as a soluble or a 
membrane-bound type, is an inert decoy or a signaling receptor for PlGF during angiogenesis. Here, we report 
that embryonic angiogenesis in mice was not affected by deficiency of PlGF (Pgf-/-). VEGF-B, another ligand of 
VEGFR-1, did not rescue development in Pgf-/- mice. However, loss of PlGF impaired angiogenesis, plasma 
extravasation and collateral growth during ischemia, inflammation, wound healing and cancer. Transplantation 
of wild-type bone marrow rescued the impaired angiogenesis and collateral growth in Pgt-/- mice, indicating that 
PlGF might have contributed to vessel growth in the adult by mobilizing bone-marrow-derived cells. The 
synergism between PlGF and VEGF was specific, as PlGF deficiency impaired the response to VEGF, but not to 
bFGF or histamine. VEGFR-1 was activated by PlGF, given that anti-VEGFR-1 antibodies and a Src-kinase 
inhibitor blocked the endothelial response to PlGF or VEGF/PlGF. By upregulating PlGF and the signaling 
subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the 'angiogenic switch' in 
many pathological disorders. 
 
Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating the VEGF tyrosine kinase 
receptor-2 (VEGFR-2/KDR)1,2. Little is known, however, about other VEGF homologs such as placental growth 
factor (PlGF)3. Indirect evidence points to a role for PlGF in placental development4, whereas recombinant PlGF 
stimulates angiogenesis in particular conditions and induces vascular permeability when co-injected with VEGF 
(refs. 5,6), but the role of endogenous PlGF remains unknown7,8. PlGF, VEGF and another homolog, VEGF-B, 
all bind to VEGF receptor-1 (VEGFR-1/Flt-1)9,10. Loss of VEGFR-1 disrupted normal vascular development11, 
but deletion of its tyrosine kinase domains allowed normal embryonic angiogenesis12, indicating that VEGFR-1 
might function as an inert 'decoy' by binding VEGF and thereby regulating the availability of VEGF for 
activation of VEGFR-2. Such a decoy function might be particularly attributed to the soluble VEGFR-1, an 
alternatively processed type of VEGFR-1 which contains the extracellular ligand-binding domains, but lacks the 
signaling tyrosine kinase domains13,14. 
PlGF has been proposed to stimulate angiogenesis by displacing VEGF from the 'VEGFR-1 sink', thereby 
increasing the fraction of VEGF available to activate VEGFR-2 (ref. 6). Alternatively, PlGF might stimulate 
angiogenesis by transmitting intracellular signals through VEGFR-1 (refs. 9,10,16). However, VEGFR-1 has 
weak tyrosine kinase activity and its intracellular signals are not well understood. PlGF might also affect 
angiogenesis by forming heterodimers with VEGF, but their role is controversial16,17. Due to lack of available 
inhibitors of PlGF or VEGFR-1, their role in pathological angiogenesis could not be demonstrated thus far.  
To examine the role of PlGF in angiogenesis, we inactivated the gene expressing PlGF (Pgf) in mice. 
Unexpectedly, the absence of PlGF—even in combination with a loss of VEGF-B—had a negligible effect on 
vascular development. However, PlGF deficiency reduced pathological angiogenesis, permeability and collateral 
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growth in ischemia, inflammation and cancer. These genetic studies unveil a synergism between PlGF and 
VEGF in pathological angiogenesis, which might have therapeutic implications for either stimulating or 
inhibiting angiogenesis. 
 
Fig. 1 Normal vascular development but impaired tumor angiogenesis in Pgf-/-mice, a, Western blotting for VEGFR-1. 
Membrane-associated VEGFR-1 (Mr ~190-200 kD) represents only 2% and 30% of total VEGFR-1 in placenta and ischemic myocardium, 
respectively. Soluble VEGFR-1 (Mr ~100-110kD). Lanes 1-2: placental extract at E9.5 and E.15.5. Lane 3: E15.5 placental extract, mixed 
with VEGF and PlGF and immuno-precipitated using anti-VEGF and anti PlGF anti-bodies. Lane 4, Myocardial infarct (Ml) extract, b-d, 
Labeling of vitelline blood vessels upon binding of [125I]VEGF165 to E9.5 yolk-sac sections (b). Excess cold VEGF (d) but not PlGF (c) 
almost completely eliminated labeling, e and f, Toluidine blue-stained section of a corpus luteum, revealing more numerous and larger 
vessels in wild-type (e) than in Pgf-/- (f) mice. For clarity, vessels were traced by white lines, g-i, Macroscopic pictures of wild-type (g), Pgf-/- 
(h) and Vegf-/- (i) ES-cell-derived tumors, revealing the hemorrhagic (red) appearance of the large wild-type tumor, in contrast to the small 
hypovascular (white) Pgf' and Vegf-/- tumors. j, Densities (vessels/optical field) of vessels of different size in wild-type tumors in wild-type 
mice, and Pgf-/- or Vegf-/- tumors in Pgf-/- mice.  wild-type;  Pgf-/-;  Vegf-/-. *, P< 0.05 versus wild-type. k and i Endoglin 
immunostaining, revealing large vessels in wild-type fibrosarcoma (k) but only small capillaries in Pgf-/- fibrosarcoma (l). Scale bars: 25 µm 
(b-f), 4 mm (g-i) and 50 µm (k and l). 
 
 
 
Normal embryogenesis and subtle vascular defects in Pgf-/- mice 
We inactivated Pgf by deleting exons 3-6 and confirmed the deletion by Southern- and northern-blot analyses 
and ELISA (< 0.5 pg PlGF/mg in Pgf-/- mice; data not shown). Pgf-/- mice from Pgf-/- or Pgf-/- breeding pairs were 
born at a mendelian frequency and were healthy and fertile. Although PlGF was expressed in wild-type embryos 
at embryonic day (E)10.5 (33 ± 7 pg/mg protein; n = 6; mean ± s.e.m.), vascular development in Pgf-/- embryos 
was normal (data not shown). PlGF levels were 60% lower, however, than VEGF levels (81 ± 4 pg/mg; n = 8) 
and PlGF was only 10% as potent as VEGF in enlarging embryonic vessels after intracardial injection in cultured 
E8.5 wild-type embryos (data not shown). 
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VEGFR-1 is the only known signaling receptor for PlGF. However, western-blot (Fig. 1a), radioligand binding 
(Fig. 1b-d) and quantitative reverse transcriptase (RT)-PCR (data not shown) analyses revealed that most 
VEGFR-1 in the embryo from E9.5 onwards was present as a soluble form. Consistent with an inhibitory decoy 
role of VEGFR-1, intracardial injection of VEGFR-1 antibodies in early-stage embryos stimulated vascular 
development, whereas VEGFR-2 antibodies blocked it (data not shown). Although more VEGF would be bound 
by VEGFR-1 in the absence of PlGF, plasma VEGF levels were not reduced in Pgf-/- embryos (-65 pg/ml in 
wild-type embryos versus -84 pg/mg in Pgf-/- embryos at E15.5). This might be due to a compensatory increase 
in production of VEGF in Pgf-/- embryos (81 ± 4 pg/mg in wild-type embryos versus 118 ± 11 pg/mg in Pgf-/- 
embryos at E10.5; n = 8; P < 0.01). Other angiogenic molecules (VEGFR-1, VEGF-B, VEGF-C and 
angiopoietin-1) were comparably expressed in Pgf-/- embryos (data not shown). 
VEGF-B is another ligand of VEGFR-1 (ref. 18), but loss of VEGF-B (Vegfb-/-) does not affect vascular 
development19. Although VEGF-B could have rescued vascular development in Pgf-/- mice, Vegfb-/- Pgf-/- mice 
were born at a normal mendelian inheritance, were apparently healthy and fertile, had a normal life span and 
were without obvious vascular defects (data not shown). This indicates that the individual VEGFR-1 ligands 
may have distinct functions in angiogenesis. 
We observed no structural vascular defects in Pgf-/- mice after birth, except for a subtle remodeling defect of 
retinal vessels (data not shown). Fewer vessels developed in corpora lutea at 4.5 days of pregnancy in Pgf-/- mice 
(vessels/mm2: 910 ± 62 in 6 wild-type mice versus 430 ± 80 in 6 Pgf-/- mice; P< 0.005; Fig. 1e and f), but did not 
impair reproduction. Thus, loss of PlGF impaired VEGF-dependent retinal and luteal angiogenesis. 
Fig. 2 Impaired retinal and myocardial angiogenesis in Pgf mice, a and b, Impaired ischemic retinal angiogenesis in Pgf mice 
(fluoro-angiogra-phy). Numerous foci of neovascularization (arrowheads) and large dialated and tortuous retinal vessels in wild-type (a) but 
not in Pgf mice (b). c and d, Immunostaining of VEGFR-1 in a wild-type mouse, revealing minimal expression during hyperoxia (P12; c) and 
significant upregulation in retinal vessels (arrowheads) after 1 d of ischemia (P13; d). e, Loss of PlGF reduces the number of endothelial cells 
and neovascular tufts in the vitreous cavity. *, P < 0.05 versus wild-type in the vitreous cavity, f and g, Thrombomodulin (TM) staining of 
endothelium, revealing more numerous vessels in wild-type (f) than in Pgf (g) myocardial infarcts, h and i, In situ hybridization revealing 
undetectable PlGF expression in normal myocardium (h) and upregulation of PlGF in ischemic cardiomyocytes and in vessels infiltrating the 
infarct (h and i; wild-type mice).j and k, Immunostaining revealing that VEGFR-1 expression is undetectable in quiescent myocardial vessels 
(j), but induced in angiogenic vessels infiltrating the infarct (j and k; wild-type mice). Scale bars: 200 µm (a and b), 25 µm (c and d), 50 µm 
(f, g and i-k) and 100µm (h). 
 
Impaired tumor angiogenesis in Pgf-/- mice 
PlGF is variably upregulated in tumors8.20-22 and its role in tumor angiogenesis remains ill defined. Therefore we 
grew embryonic stem (ES)-cell-derived tumors of either genotype in athymic nu/nu wild-type or Pgf-/- mice for 
four weeks. When both tumor and host expressed PlGF, tumors were large and highly vascularized (4 ± 1 g; n = 
8; Fig. 1g and j). In contrast, when they both lacked PlGF, tumors remained small and poorly vascularized (1.0 ± 
0.3 g; n = 8; Fig. 1h and j), comparable to the reduced growth and angiogenesis of VEGF-deficient tumors (0.3 ± 
0.1 g; n = 10; Fig. 1 i and j). When either tumor or host produced PlGF, tumor growth and angiogenesis were 
intermediate, indicating that production of PlGF by tumor- and host-derived tissue contributed to tumor 
angiogenesis. Coverage of tumor vessels by smooth muscle cells was not affected by Pgf genotype. We 
confirmed the role of PlGF in tumor angiogenesis using ras-transformed fibroblasts. Pgf-/- fibrosarcomas were 
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smaller than wild-type fibrosarcomas when implanted in nu/nu wild-type mice (2.8 ± 0.2 g versus 5.5 ± 0.6 g; ∏ 
= 7; P < 0.05), and, although vascular densities were comparable in both tumors (~550 vessels/mm2), Pgf-/- 
fibrosarcomas contained vessels with a smaller lumen than wild-type fibrosarcomas (110 ± 18 µm2 versus 210 ± 
12 µm2; n = 7; P < 0.05; Fig. 1k and 1). As revealed by in situ hybridization analysis of wild-type 
fibrosarcomas, PlGF was expressed in endothelial and tumor cells, whereas VEGFR-1 was highly expressed in 
tumor vessels (data not shown). Wild-type tumors expressed large amounts of PlGF (85 ± 12 pg/mg protein; n = 
5) and VEGF (430 ± 40 pg/mg protein; n = 5). However, reduced tumor angiogenesis in Pgf-/- tumors did not 
result from reduced expression of VEGF, VEGF-B or VEGF-C (data not shown). Thus, loss of PlGF impaired 
growth of VEGF-dependent tumors. 
Fig. 3 Impaired pathological arteriogenesis in Pgf-/-mice, a, Time course of skin wound healing.  wild-type;  Pgt'~ mice; n = 15 mice; 
P < 0.05 versus wild-type, b and c, Macroscopic view of impaired skin wound healing in Pgf-/- (c) as compared with wild-type (b) mice, d 
and e, Smooth muscle α-actin (SMA) staining, revealing impaired coverage of newly formed vessels by smooth muscle cells (arrowheads) in 
Pgf-/- (e) as compared with wild-type (d) mice, f and g, PlGF immunostaining of human skin, revealing minimal expression in normal skin (ƒ) 
and upregulation during chronic eczema (g). Scale bars: 4 mm (b and c), 50 µm (d-g). 
 
Reduced angiogenesis in ischemia in Pgf-/- mice 
During ischemic retinopathy, increased VEGF levels stimulate vitreous neovascularization. Previous studies 
reported minimal changes in PlGF transcripts23 or increased PlGF protein levels24, but the role of PlGF in retinal 
neovascularization remains unknown. We induced capillary dropout in the retina by exposing seven-day-old (P7) 
mice to 80% oxygen for five days. Upon return to normoxia at P12, the hypovascular retina became ischemic, 
upregulated VEGF and induced venous dilation, arterial tortuosity and capillary growth in the vitreous chamber 
(Fig. 2a and e). Loss of PlGF significantly protected mice against intravit-reous neovascularization (n = 19; P < 
0.005; Fig. 2b and e), venous dilatation and arterial tortuosity (Fig. 2 b). During retinal ischemia, VEGFR-1 was 
induced in vascular sprouts (Fig. 2 c and d), whereas VEGF and PlGF were significantly upregulated (pg 
VEGF/mg protein: 98 ± 12 at P12 versus 850 ± 18 at P13; n = 7; P < 0.005 and pg PlGF/mg protein: 10 ± 2 at 
P12 versus 38 ± 3 at P13; n = 3; P < 0.05). VEGF levels were comparable, however, in both genotypes (data not 
shown). 
We analyzed revascularization of myocardial infarcts after ligating the left anterior descending coronary artery25. 
Compared with wild-type mice, Pgf-/- infarcts contained approximately 20% fewer vessels (vessels/mm2: 134 ± 9 
in wild-type mice versus 111 ± 5 in Pgf-/- mice; n = 12 to 24; P< 0.05; Fig. 2f and g). VEGF and PlGF levels 
(expressed per mg protein) were increased in infarct borders where angiogenesis occurs: normal myocardium 
produced 22 ± 2 pg VEGF and 8 ± 1 pg PlGF, whereas infarcts produced 52 ± 6 pg VEGF and 102 ± 8 pg PlGF 
Published in:  Nature Medicine (2001), vol. 7, iss.5, pp. 575-583 
Status: Postprint (Author’s version) 
 
(n = 5; P< 0.05). Expression of VEGF, VEGFR-2 and endoglin in infarcts was comparable in both genotypes 
(data not shown). PlGF and VEGFR-1 were undetectable in quiescent vessels in normal myocardium, but were 
upregulated in angiogenic vessels and macrophages infiltrating ischemic myocardium (Fig. 2h-k). 
Administration of recombinant hPlGF-1 to Pgf-/- mice rescued infarct revascularization (data not shown), which 
was associated with increased accumulation of macrophages (Mac-3-positive area/infarct area: 1.8 ± 0.4% after 
vehicle versus 5.0 ± 0.7% after PlGF; n = 4; P < 0.05). Taken together, loss of PlGF impaired VEGF-dependent 
retinal and myocardial angiogenesis. 
Role of PlGF during skin wound healing 
Healing of skin incisions progressed more slowly in Pgf-/- mice versus wild-type (Fig. 3a-c). Both genotypes 
contained comparable densities of vessels in unwounded skin (~220 vessels/mm2) and of new capillaries 
infiltrating into the wound (vessels/mm2: 240 ± 50 in wild-type mice versus 180 ± 50 in Pgf-/- mice; n = 5; P = 
NS). However, wild-type mice contained more smooth muscle-coated vessels than naked vessels (vessels/mm2: 
75 ± 18 smooth muscle α-actin-positive vessels versus 40 ± 7 naked; n = 5), whereas the opposite was true for 
Pgf-/-mice (vessels/mm2: 84 ± 13 naked versus 30 ± 10 mature vessels; n = 5; P < 0.05 versus wild-type; Fig. 3d 
and e). VEGFR-1 and VEGFR-2 were induced in wounded skin vessels (data not shown), whereas PlGF 
expression was upregulated in endothelial cells and in the hyperplastic epidermis at the wound edge, where new 
vessels formed (Fig. 3f and g). VEGF expression was comparably increased in the hyperplastic epidermis in both 
genotypes (see below). Coverage of pulmonary vessels by smooth muscle cells was also impaired in Pgf-/- mice 
after exposure to hypoxia (data not shown). 
 
Table 1; Role of PlGF and VEGF in endothelial survival, migration and proliferation 
Effect Treatment Wild-type Pgf-/-
Apoptosis 
(% of vehicle control) Vehicle 100 100 
 PlGF (100 ng/ml) 97 ±9 96 ±10 
 VEGF (100 ng/ml) 22 ±8* 93 ±10 
 VEGF (100 ng/ml) + PP2 (100 µM) ND 102 ±5 
 VEGF + PlGF (50 ng/ml each) ND 50 ±13* 
 VEGF + PlGF (100 ng/ml each) ND 25 ±5* 
 VEGF + PlGF (100 ng/ml each) + anti-VEGFR-1 (50 µg/ml) ND 100 ±11 
 VEGF + PlGF (100 ng/ml each) + anti-mPlGF (50µg/ml) ND 75 ±9 
 VEGF + PlGF (100 ng/ml each) +PP2 (100µM) ND 107 ±5 
 VEGF/PlGF heterodimer (100 ng/ml) ND 17±7* 
Migration 
(migrating cells) Vehicle 5±3 6±2 
 PlGF (100 ng/ml) 7 ±2 8±2 
 VEGF (100 ng/ml) 88 ±9* 24 ±2* 
 VEGF + PlGF (100 ng/ml each) 92 ±5* 97 ±3* 
 bFGF (50 ng/ml) 96 ±6* 102 ±13*
 bFGF (50 ng/ml) + PlGF (100 ng/ml) 94 ±5* 100 ± 6* 
Proliferation 
(cells/well) Vehicle 10± 1 10± 1 
 PlGF (100 ng/ml) 11 ±2 8±2 
 VEGF (100 ng/ml) 34 ±2* 15 ± 1* 
 VEGF + PlGF (100 ng/ml each) 35 ±2* 38 ±2* 
 bFGF (50 ng/ml) 39 ±3* 43 ±2* 
 bFGF (50 ng/ml) + PlGF (100 ng/ml) 34 ±2* 39 ±2* 
Data represent the mean ± s.d. of 9 to 12 experiments. Migration and proliferation are expressed in absolute number of migrating and 
proliferating cells; apoptosis is expressed as a percent of the control (vehicle-treatment). Anti-mPlGF, anti-murine PlGF antibodies; ND, not 
determined. *, P< 0.05 versus control (vehicle). 
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Reduced collateral growth in Pgf-/- mice 
We studied growth of collateral arteries after ligation of the femoral artery. Collaterals in non-occluded limbs 
were small in both genotypes, but became tortuous and enlarged in wild-type but not Pgf-/- mice after ligation 
(Fig. 4a-c). PlGF levels were 45% higher in ligated vessels than in control vessels (4.5 ± 0.9 pg PlGF/mg protein 
versus 3.1 ± 0.9 pg PlGF/mg protein; n = 4; P < 0.05 by paired t-test). Macrophages, known to play an essential 
role in collateral growth26, infiltrated more collaterals in wild-type than in Pgf-/- mice (68% of 66 wild-type 
collaterals versus 43% of 67 Pgf-/- collaterals; P < 0.05 by χ-square analysis; n = 5 mice; Fig. 4d and e). 
Macrophages may have been recruited by PlGF, produced by activated endothelial cells, as PlGF is known to be 
chemoattractive for monocytes/macrophages27. Activated macrophages themselves may be another source of 
PlGF in growing collaterals, as they produce PlGF in culture (8 ± 2 Pgf per 1 × 103 hprt transcripts; n = 5) and 
stained strongly for PlGF in vivo (Fig. 4h). During collateral growth, extravasated fibronectin provides a scaffold 
for migrating smooth muscle cells. Fibronectin leaked out in 70% of 80 wild-type collaterals, but in only 25% of 
83 Pgf-/- collaterals after ligation (n = 5 mice; P< 0.05 by χ-square; Fig. 4f and g). A role for PlGF in vascular 
permeability was further demonstrated in other assays (see below). Thus, PlGF may stimulate collateral growth 
by affecting monocyte recruitment, plasma extravasation and growth of endothelial and smooth muscle cells (see 
below). 
 
Fig. 4 Impaired collateral growth in Pgf-/- mice, a and b, Macroscopic view of collateral arterioles (visualized by bismuth 
gelatinography; arrowheads) in the hindlimb after ligation of the deep femoral artery (FA), revealing enlarged, tortuous collaterals in wild-
type (a) but not in Pgf-/- (b) mice, c, Quantification of the lumen area of the collateral vessels in the non-occluded and occluded limb, and the 
rescue of adaptive arteriogenesis by transplantation of wild-type bone marrow in Pgf-/- mice (+/+ —> -/-). non-ligated;  ligated. Mean ± 
s.e.m. of at least 10 mice. *, P< 0.05 versus non-ligated. d and e, Mac3 immunos-taining, revealing more numerous macrophages 
accumulating and infiltrating in wild-type (d) than in Pgf-/- (e) collaterals 3 d after occlusion, f and g, Fibronectin immunostaining, revealing 
larger extravasated fibronectin deposits around wild-type (f) than around Pgf-/- (g) collaterals 3 d after occlusion. h, PlGF immunostaining of 
macrophages in a human brain infarct. Scale bars: and 50 µm (d-g), 10 µm (h). 
 
Loss or inhibition of PlGF reduced plasma extravastion 
Recombinant PlGF stimulates vascular leakage5 6, but no role for endogenous PlGF in plasma extravasation has 
been identified. Topical administration of VEGF on microvessels in cremaster muscle stimulated extravasation 
of fluorescent dextran in wild-type mice, but only minimally in Pgf-/- mice (Fig. 5a-e). Notably, histamine 
induced a comparable response in both genotypes, indicating that PlGF specifically amplified the effect of 
VEGF (Fig. 5e). We observed a similar reduced plasma extravasation in Pgf-/- mice in the Miles assay during 
skin wound healing, after subcutaneous implantation of a perforated polyethylene ball or in a model of delayed 
skin hypersensitivity (data not shown). PlGF levels were upregulated in endothelial cells and in hyperplastic 
keratinocytes in wounded or inflamed skin and increased from lower than 1 pg/mg protein in normal to 27 ± 6 
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pg/mg protein in wounded skin (n = 5; P < 0.005). VEGF was comparably upregulated in both genotypes (2 ± 1 
pg/mg versus 97 ± 15 pg/mg in wild-type mice; n = 5; P < 0.05; and 4 ± 1 pg/mg versus 108 ±15 pg/mg in Pgf-/- 
mice; n = 5; P < 0.05), whereas endothelial VEGFR-1 expression was induced in wounded skin (data not 
shown). Few specific therapeutic strategies are currently available to block plasma extravasation. Neutralizing 
anti-PlGF antibodies reduced vascular leakage in wild-type mice after application of mustard oil on their ears 
(relative absorbance units × 1000/ear: 13 ± 3 after mineral oil; 53 ± 7 after mustard oil plus control IgGs; 26 ± 5 
after mustard oil plus anti-PlGF; n = 5; P < 0.05 versus control antibodies; Fig. 5f and g). We obtained similar 
results after intradermal injection of VEGF (data not shown). Recombinant PlGF restored the reduced plasma 
extravasation in Pgf-/- mice (data not shown). 
Role of PlGF in mobilization of bone-marrow-derived cells 
VEGF recruits bone-marrow-derived cells to sites of pathological angiogenesis, but the role of PlGF remains 
undefined28,29. Because bone-marrow-derived cells contribute to capillary ingrowth in matrigel implants (data not 
shown), mice were transplanted with congenic bone marrow and capillary ingrowth in matrigel, supplemented 
with the VEGF165 isoform, and quantified by measuring the hemoglobin (Hb) content per implant. Matrigel 
angiogenesis was abundant when both the donor bone marrow and the host vessels produced PlGF (0.29 ± 0.05 g 
Hb/dl; n = 7), but minimal when the bone marrow and host lacked PlGF (0.05 ± 0.01 g Hb/dl; n = 7; P<0.05). 
Capillaries still infiltrated the ma-trigel in wild-type mice transplanted with Pgf-/- bone marrow (0.26 ± 0.07 g 
Hb/dl; n = 9), indicating that PlGF production by vessel-wall-associated endothelial cells was sufficient for 
angiogenesis. Notably, when a Pgf-/- recipient was transplanted with wild-type bone marrow, matrigel 
angiogenesis still occurred (0.17 ± 0.07 g Hb/dl; n = 7), indicating that production of PlGF by bone-marrow cells 
can stimulate angiogenesis at distant sites. Transplantation of wild-type bone marrow in Pgf-/- mice also rescued 
the impaired collateral enlargement after ligation of the femoral artery, possibly by mobilizing PlGF-producing 
monocytes/macrophages to the collaterals (Fig. 4c). PlGF specifically modulated the VEGF response, as 
angiogenesis in matrigel supplemented with bFGF was comparable in both genotypes (0.28 ± 0.02 g Hb/dl in 
wild-type mice versus 0.25 ± 0.02 g Hb/dl in Pgf-/ -mice; n = 15; P = NS). 
PlGF modulates the endothelial response to VEGF 
To determine whether the amplification of the VEGF response by PlGF resulted from direct stimulation of 
endothelial cells, we studied capillary outgrowth in intact aortic rings. We used Pgf-/-aortic rings and serum to 
avoid effects of endogenously produced PlGF. At 20 ng/ml, PlGF or VEGF alone minimally stimulated capillary 
outgrowth (< 1 capillary/aorta). However, a combination of VEGF and PlGF strongly stimulated capillary 
outgrowth (8 ± 1 capillaries/aortic ring; 4 ± 2 branches/capillary; 0.37 ± 0.05 µm capillary length; n = 9). A 
higher concentration of VEGF (60 ng/ml) stimulated capillary outgrowth from Pgf-/- aortic rings, indicating that 
PlGF amplified, but did not determine the VEGF response (13 ± 2 capillaries/aortic ring; 8 ± 2 
branches/capillary; 0.35 ± 0.02 µm capillary length). A high concentration of PlGF (50 ng/ml) stimulated 
capillary outgrowth (13 ± 3 capillaries/aortic ring; n = 5). Because PlGF alone (in the absence of VEGF) did not 
stimulate isolated endothelial cells (see below), PlGF probably stimulated capillary outgrowth by amplifying 
endogenous VEGF in aortic rings. We observed a similar amplification of the VEGF-response by PlGF in other 
endothelial cells (data not shown). 
We also observed the interaction between VEGF and PlGF using capillary endothelial cells from both genotypes 
(Table 1). VEGF stimulated the migration, growth and survival of wild-type cells. Compared with the wild type 
response, VEGF stimulated migration by 25%, proliferation by 40% and survival by 7% in Pgf-/- cells. However, 
both genotypes responded comparably to bFGF. A high concentration of PlGF alone did not affect the response 
of wild-type endothelial cells to VEGF, presumably because these cells produced sufficient PlGF (data not 
shown). However, even at low doses, PlGF dose-depen-dently restored the impaired VEGF-response of Pgf-/- 
endothelial cells. Antibodies specific for VEGFR-1 completely blocked the response of Pgf-/- cells to a 
combination of VEGF plus PlGF, indicating that PlGF activated VEGFR-1. VEGF/PlGF het-erodimers also 
stimulated the survival of Pgf-/- endothelial cells (Table 1). Thus, PlGF, though ineffective by itself, amplifies the 
VEGF response by activating VEGFR-1. 
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Fig. 5 Modulation of permeability and of VEGF-response by PlGF. a-d Intravital microscopy, revealing extravasation of 
fluorescent dextran from microvessels in the cremaster muscle at 0 (a and c) and 60 (b and d) min after topical application of VEGF in wild-
type (a and b) but not in Pgf-/- (c and d) mice. Scale bars: 50 µm (a-d). e, Quantification of extravasated dextran, revealing extravasation in 
response to VEGF and histamine in wild-type mice, but only to histamine in Pgt-/- mice. wild-type; , Pgf-/-mice. *, P< 0.05 versus wild-
type (n = 10 mice), f and g, Mustard-oil-induced extravasation of Evans blue in the left ear of wild-type mice is reduced by antibodies against 
PlGF (g) but not by control IgGs (f). h, Schematic model of the role of VEGF, PlGF, VEGFR-1 and VEGFR-2. In the embryo, VEGF 
induces angiogenesis by activating VEGFR-2. VEGFR-1 is primarily expressed as an inhibitory soluble receptor (sVEGF-R1) which 
functions as a 'sink' for VEGF, with only minimal levels of membrane-associated VEGFR-1. i, In pathological conditions, PlGF is 
upregulated and stimulates angiogenesis via displacement of VEGF from VEGF-R1 to VEGF-R2 and via activation of VEGFR-1, of which a 
larger fraction is membrane-associated. PlGF-mediated activation of VEGFR-1 synergizes with VEGF-mediated activation of VEGFR-2 to 
induce a stronger angiogenic response. Dotted lines represent low expression; solid lines denote high levels of expression. The inhibitory 
pathway is indicated in red. 
 
 
 
Upregulation and signaling of membrane-associated VEGFR-1 
The inhibition of the endothelial response to PlGF by VEGFR-1 antibodies indicated that VEGFR-1 transmitted 
intracellular signals. For PlGF to cause signaling, VEGFR-1 must be membrane-associated. In mid-term 
placentas, only 2 ± 0.5% of total VEGFR-1 was membrane-associated, whereas 30 ± 2% of VEGFR-1 was 
membrane-bound in ischemic myocardium (n = 3; P < 0.005; Fig. 1a). Quantitative RT-PCR analysis confirmed 
the increased membrane-localization of VEGFR-1 during pathological angiogenesis (data not shown). To 
examine whether PlGF induced intracellular signaling, we studied the role of the Src-family kinases in the 
response of Pgf-/- endothelial cells to VEGF and PlGF (Table 1). Src-kinases have recently been implicated in 
responses to VEGF (refs. 30,31), but their role in the response to PlGF is unknown. The selective Src-kinase 
inhibitor pyrazolopyrimidine (PP2) did not affect the response of Pgf-/- endothelial cells to VEGF, but 
completely blocked the PlGF-dependent amplification of the VEGF response in Pgf-/- endothelial cells. 
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DISCUSSION 
PlGF and VEGFR-1 have received little attention in angiogenesis research3. The present analysis indicates that 
PlGF—via activation of VEGFR-1—specifically potentiates the angiogenic response to VEGF, but not to bFGF. 
In contrast to the essential role of VEGF in physiological and pathological angiogenesis1,2,32, the role of PlGF is 
restricted to pathological conditions and is therefore a possible target for therapy. 
Several mechanisms might explain why PlGF had a negligible role in vascular development (Fig. 5h and i). First, 
PlGF may be unable to displace VEGF from VEGFR-1, because of its lower expression levels in the embryo and 
its lower affinity for VEGFR-1 compared with VEGF (ref. 3). Second, VEGF was upregulated in compensation 
for the absence of PlGF. Third, the minimal levels of membrane-associated VEGFR-1 in the embryo might be 
insufficient to transmit PlGF-dependent angiogenic signals. VEGFR-1 is predominantly soluble and antibodies 
against VEGFR-1 stimulate angiogenesis in embryos, confirming that VEGFR-1 is primarily an inert 'sink' for 
VEGF during development11,12. Fourth, the need for amplification of the VEGF response by PlGF in the adult 
might be explained by a requirement for greater responses to VEGF to mediate pathological rather than 
embryonic angiogenesis. In at least several pathological conditions, VEGF and PlGF levels exceeded those 
found in the embryo. VEGF-B did not rescue vascular development of Pgf-/- embryos, even though it also binds 
to VEGFR-1 (refs. 9,10), raising the question of whether the individual VEGFR-1 ligands have distinct functions 
in vivo. 
Previous studies reported that exogenously administered PlGF stimulates angiogenesis or permeability in 
particular conditions5,6, but they did not evaluate the endogenous role of PlGF in the adult. The present findings 
indicate that by affecting vascular growth and remodeling, PlGF contributes to the pathogenesis of several 
disorders with high morbidity. Although our findings do not exclude the possibility that PlGF activates 
endothelial cells independently of VEGF (refs. 15,33), PlGF was found to stimulate angiogenesis by synergizing 
with VEGF. When new blood vessels form in the adult endothelial cells become more responsive to VEGF by 
upregulating PlGF and VEGFR-1, (Fig. 5h and i). Apart from this autocrine pathway, PlGF from paracrine 
sources (malignant cells, macrophages, ischemic cardiomyocytes and so forth) might also enhance the 
angiogenic activity of VEGF. PlGF might increase tumor angiogenesis depending on whether tumors up-regulate 
PlGF (refs. 8, 20-22). The effect of PlGF on the vasculature was quantitatively and qualitatively dependent on 
the tissue microenvironment. For instance, PlGF stimulated endothelial growth in ischemic retina, but promoted 
arterial remodeling in ischemic limbs. In addition, depending on the tumor, PlGF increased the number or the 
size of new vessels. A similar tissue-specific role for VEGF is now being recognized5, even though the 
underlying mechanisms remain largely undefined. 
Several mechanisms might explain the role of PlGF in pathological, but not physiological angiogenesis. First, 
PlGF and VEGFR-1 are minimally expressed in adult quiescent vasculature, but are markedly upregulated 
during pathological conditions. Second, PlGF might enhance the angiogenic response to VEGF by forming 
VEGF/PlGF heterodimers, which have been detected in tumors and are upregulated by hypoxia16,17. Third, PlGF 
activates VEGFR-1 to transmit angiogenic signals—as supported by our findings that antibodies against 
VEGFR-1 blocked the angiogenic activity of PlGF in vitro (this study) and in vivo (manuscript in preparation). If 
the only function of PlGF was to 'fill up an inert VEGFR-1 sink', antibodies against VEGFR-1 should stimulate, 
not inhibit, angiogenesis. The increased membrane-localization of VEGFR-1 in pathological angiogenesis, as 
compared with embryonic angiogenesis, and the inhibition of PlGF by the Src-kinase inhibitor are also 
consistent with a role for PlGF and VEGFR-1 in angiogenic signaling. Rather than contradicting the previous 
suggestion that PlGF stimulates angiogenesis by displacing VEGF from the 'VEGFR-1 sink5,6, our data provide 
evidence for an additional role of PlGF in transmitting angiogenic signals. Because both mechanisms could be 
operational at the same time (for example, PlGF displaces VEGF from VEGFR-1 and activates VEGFR-1), it 
remains to be determined to what extent and under which conditions VEGFR-1 is a decoy and/or a signaling 
receptor for PlGF. Fourth, PlGF is a chemoattractant for inflammatory cells, a hallmark of pathological 
angiogenesis and collateral growth25,32. The reduced recruitment of macrophages likely contributed to the 
reduced collateral growth in Pgf-/- mice, whereas transplantation of wild-type bone marrow rescued their 
collateral expansion. Finally, PlGF might also stimulate pathological angiogenesis by mobilizing bone-marrow-
derived cells. Whether PlGF affects mobilization of bone-marrow-derived an-gioblasts or hematopoietic stem 
cells remains unknown. 
Conditional VEGF gene-inactivation and inhibitor studies in adult mice have revealed that the adult quiescent 
vasculature becomes less dependent on VEGF for its maintenance34. However, during pathological conditions—
such as ischemia, inflammation or malignancy—angiogenic endothelial cells are stimulated by increased VEGF 
levels. The molecular mechanisms by which adult endothelial cells are induced to rapidly grow ('angiogenic 
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switch') are still incompletely understood. Our findings indicate that PlGF might contribute to this switch by 
amplifying VEGF. An outstanding question is therefore whether PlGF could be used for therapeutic 
angiogenesis of ischemic cardiovascular disease, or whether inhibition of PlGF might suppress pathological 
angiogenesis in tumors, inflammatory disorders and diabetic retinas (manuscript in preparation). The present 
findings that anti-PlGF antibodies blocked permeability indicate a novel treatment strategy for vascular leakage 
syndromes as well. 
METHODS 
Generation of Pgf-/- mice.  
To inactivate the Pgf gene in embryonic stem (ES) cells, pPNT. Pgf was constructed containing a 8-kb Ncol 
fragment (exons 1 and 2 and part of exon 3 until nucleotide 265 of the murine Pgf cDNA), a neomycin 
phosphotransferase (neo) cassette, and a 5-kb BamHI fragment (exon 7). Probes for Southern-blot analysis 
included a 380-bp fragment obtained by PCR using 5'-GAATTCAATGAGTTAAGGGTG -3' and 5'- 
AATACTACAGTTATAGACTA -3' primers and a neo probe. Pgf-/- ES clones were obtained by culturing Pgf-/- 
ES clones in 1800 µg/ml G418. Targeted ES clones were used to generate chimeric mice, which were test-bred 
with Swiss females for germline transmission as described35.  
Gene expression, morphology, antibodies and embryo culture.  
Western and northern blotting, real-time RT-PCR, immunostaining and in situ hybridization were performed as 
described35. VEGFR-1 was immunoblotted after incubation with heparin-sepharose using VEGFR-1-specific 
antibodies (Sigma; clone Flt11). To demonstrate binding of VEGF and PlGF to soluble VEGF-R1, 500 µg 
placental extract was incubated with 500 ng VEGF and 1 µg PlGF-2 for 1 h at room temperature, 
immunoprecipitated with anti-VEGF and anti-PlGF antibodies and immunoblotted for VEGF-R1. Radioligand 
binding studies with [125l]-labeled VEGF165 were performed as described", except that a 60-fold molar excess of 
cold PlGF or VEGF was used as competitor. The following antibodies were used for immunostaining: rat 
antibody against mouse VEGFR-1 (MF1; Imclone, New York, New York; characterization will be reported 
elsewhere; goat antibody against mouse VEGFR-2 (R&D Systems, Abingdon, UK), rat antibody against mouse 
VEGFR-2 (DC101; Imclone)36; and rabbit antibody against human PlGF (#PA211, ReliaTech; Braunschweig, 
Germany). A murine PlGF-specific ELISA was set up, using goat antibody against murine PlGF antibodies 
(R&D), but murine VEGF was quantified with a commercially available ELISA (R&D). The following primers 
were used for RT-PCR of Pgf. 5'-TTCAGTCCGTCCT-GTGTCCTT-3'; 5'-GCACACAGTGCAGACCTTCA-3'; 
and 5'-AC-CACAGCAGC CACTACAGCGACTCA-3'. Expression levels of Pgf were normalized for hprt. The 
following immunoneutralizing antibodies were used: VEGFR-2 (DC101, Imclone)36; VEGFR-1 (MF1, Imclone); 
PlGF-2 (R&D); and isotype-matched control IgGs (Imclone and ICN, Costa Mesa, California)37. The 
recombinant proteins used were PlGF-2 (ReliaTech), VEGF165 and VEGF/PlGF heterodimer (both from R&D). 
Models of angiogenesis.  
Morphometry of angiogenesis in neonatal mice38, transplantation of congenic bone marrow (C57BI6 
background)25, ingrowth of capillaries in matrigel (containing VEGF or bFGF)39 and analysis of ES-cell-
derived40 and fibrosarcoma41 tumors were described. Luteal angiogenesis was analyzed on toluidine blue-stained 
semi-thin sections of ovaries 4.5 d after mating. Ischemic retinal neovascularization was induced by exposing P7 
neonatal mice to hyperbaric (80%) oxygen for 5 d and subsequently to room air for another 5 d, and then 
analyzed by fluorescent retinal angiography and counting endothelial cell on retinal cross-sections. Venous 
dilatation and arterial tortuosity were semi-quantitatively scored (scale: 0-3). Vascular remodeling during skin 
wound healing was analyzed within 4 d after applying a 15-mm, full-thickness skin wound42. To induce limb 
ischemia, the right femoral artery was occluded distal to the branch site of the deep femoral and the popliteal 
artery. After 7 d, mice received 0.1% adenosine, were perfused with fixative and bismuth-gelatin contrast 
medium for angiography. Collaterals in the adductor muscle were used for morphometry. Myocardial infarction 
and infarct revascularization were performed as described25. Human PlGF-1 (10 µg active dimer; Geymonat 
SpA, Anagni, Italy) was delivered using an osmotic minipump (Alzet, type 2001, Someren, the Netherlands). 
Vascular permeability.  
Mustard oil was painted on the ears of Swiss mice, and extravasation of Evans blue determined43. Antibodies 
were injected i.v. (300 µg/kg) 30 min before injection of Evans blue and application of mustard oil. For intravital 
analysis, the mouse cremaster muscle was exposed, and a flexible ovoid ring introduced into the cremaster pouch 
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to allow transillumination of the muscle, covered with carbogen-bubbled prewarmed mineral oil44. Within 10 
min after i.v. injection of FITC-labeled dextran, 150,000 (100 mg/kg), 10 µl of VEGF165 (260 nM) or histamine 
(500 nM) was topically administered. Video images of fluorescent microcirculation were recorded throughout 
the experiment for off-line analogous video image processing of the light intensity in a selected area of the video 
picture, expressed as gray values (arbitrary units). 
In vitro angiogenesis assays.  
Capillary outgrowth from cultured rings of mouse aorta in gels of rat-tail interstitial collagen (1.5 mg/ml) was 
performed as described for the rat45, except that 2.5% mouse serum was used. To quantify the number, length 
and branching of vessels, a scanned image of the aortic ring was converted to a binary image (aortic ring and 
capillaries in blue with black background; fibroblasts were subtracted). To obtain mouse capillary endothelial 
cells, mice were injected s.c. with 500 µl of matrigel containing bFGF (100 ng/ml) and heparin (100 µg/ml). 
After 7 d, the matrigel pellet was enzymatically dispersed and endothelial cells were cultured in M131 medium 
supplemented with 5% MVGS (Gibco-BRL). Cells were starved in medium with 0.5% serum for 24 h, after 
which they were stimulated with human VEGF165 and/or murine PlGF-2, or bFGF (all from R&D) for 24 h. 
Cultures were then analyzed for the total cell number (proliferation) or the number of cells migrated after scrape-
wounding (migration). For apoptosis studies, cells were cultured in RPMI 1640 medium containing 10% FCS 
(Life Technologies), 100 µg/ml heparin and 30 µg/ml endothelial cell growth supplement. Apoptosis was 
induced by withdrawal of growth factors (0.1% FCS) and quantified by measuring cytoplasmic his-tone-
associated DNA fragments (mono- and oligonucleosomes) as described37. Pyrazolopyrimidine (PP2) was from 
Calbiochem (Beeston Nottingham Forest, UK). 
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